The National Comprehensive Cancer Network (NCCN)—an alliance of leading cancer centers—has published updated data on the current impact of generic cancer medication shortages in the United States. The data come from survey responses from pharmacy directors and other clinical and administrative leaders at NCCN Member Institutions from late August. According to the results, 100% of responding cancer centers are experiencing a shortage of at least one anticancer agent, with more than 20% of centers currently experiencing shortages of five or more different medications.
Survey Reveals Widespread Shortages of Cancer Medications in U.S. Healthcare System
The National Comprehensive Cancer Network (NCCN) has reported widespread shortages of generic cancer medications across U.S. cancer centers, with all responding centers indicating a lack of at least one anticancer agent. This situation highlights systemic issues in healthcare supply chains that could resonate in countries like Iran, where access to essential medications is also a concern.
👥 Key Players
📰 What Happened
The NCCN reported that all responding cancer centers in the U.S. are facing shortages of anticancer medications, with many centers lacking multiple drugs. This highlights significant supply chain issues within the healthcare system.
- 100% of responding cancer centers reported shortages of at least one anticancer agent.
- Over 20% of centers are experiencing shortages of five or more different medications.
💡 Why It Matters
📚 Background
Cancer medication shortages are a growing concern in many healthcare systems, often linked to manufacturing issues, regulatory challenges, and economic factors.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%